文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

节拍化疗与最佳支持治疗在进展性儿童实体恶性肿瘤中的比较:一项随机临床试验

Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2017-01-01

该双盲安慰剂对照随机临床试验纳入108例至少二线化疗后进展且无治愈选择的儿童颅外非造血系统实体恶性肿瘤患者,比较口服四药节拍化疗与安慰剂。6个月无进展生存率两组无显著差异(安慰剂组100% vs 节拍化疗组96.4%,P=0.24),中位无进展生存和总生存两组相似。事后亚组分析中,接受超过3个周期及无骨肉瘤的患者似乎从节拍化疗中获益。

要点

  • 节拍化疗相比安慰剂未改善6个月无进展生存(100% vs 96.4%,P=0.24)。
  • 中位无进展生存和总生存两组相似(HR 0.69,95%CI 0.47-1.03;HR 0.74,95%CI 0.50-1.09)。
  • 事后亚组中超过3个周期及无骨肉瘤者似乎获益(HR 0.46;HR 0.39)。

核心结论

  • 在儿童颅外进展性实体恶性肿瘤患者中,节拍化疗相比安慰剂未改善6个月无进展生存。
  • 无骨肉瘤及能够耐受超过3个周期(9周)治疗的患者可能获益。

研究设计与样本

  • 双盲、安慰剂对照随机临床试验,于2013年10月1日至2015年12月31日在全印度医学科学研究所癌症中心开展。
  • 纳入5至18岁、至少二线化疗后进展且无进一步治愈选择的原发颅外非造血系统实体恶性肿瘤儿童。
  • 筛查123例,入组108例;安慰剂组52例(中位年龄15岁;男性40例[76.9%]),节拍化疗组56例(中位年龄13岁;男性42例[75.0%])。
  • 节拍化疗组接受每日塞来昔布和沙利度胺联合依托泊苷与环磷酰胺交替的四药口服节拍方案,另一组接受安慰剂。
  • 主要终点为6个月时无疾病进展的患者比例定义的无进展生存,无进展生存时长和总生存为次要终点。

主要发现

  • 中位随访2.9个月时,6个月时疾病进展比例安慰剂组为100%,节拍化疗组为96.4%(P=0.24)。
  • 中位无进展生存两组相似(HR 0.69;95%CI 0.47-1.03;P=0.07)。
  • 中位总生存两组相似(HR 0.74;95%CI 0.50-1.09;P=0.13)。
  • 事后亚组分析中,接受超过3个周期的队列无进展生存HR为0.46(95%CI 0.23-0.93;P=0.03)。
  • 事后亚组分析中,无骨肉瘤(即既非原始神经外胚层肿瘤也非骨肉瘤)的队列无进展生存HR为0.39(95%CI 0.18-0.81;P=0.01)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although oral metronomic chemotherapy is often used in progressive pediatric solid malignant tumors, a literature review reveals that only small single-arm retrospective or phase 1 and 2 studies have been performed. Skepticism abounds because of the lack of level 1 evidence. OBJECTIVES: To compare the effect of metronomic chemotherapy on progression-free survival (PFS) with that of placebo in pediatric patients with primary extracranial, nonhematopoietic solid malignant tumors that progress after at least 2 lines of chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: A double-blinded, placebo-controlled randomized clinical trial was conducted from October 1, 2013, through December 31, 2015, at the cancer center at All India Institute of Medical Sciences in children aged 5 to 18 years with primary extracranial, nonhematopoietic solid malignant tumors that progressed after at least 2 lines of chemotherapy and had no further curative options. INTERVENTIONS: One arm received a 4-drug oral metronomic regimen of daily celecoxib and thalidomide with alternating periods of etoposide and cyclophosphamide, whereas the other arm received placebo. Disease status was assessed at baseline, 9 weeks, 18 weeks, and 27 weeks or at clinical progression. MAIN OUTCOMES AND MEASURES: The primary end point was PFS as defined by the proportion of patients without disease progression at 6 months, and PFS duration and overall survival (OS) were secondary end points. RESULTS: A total of 108 of the 123 patients screened were enrolled, with 52 randomized to the placebo group (median age, 15 years; 40 male [76.9%]) and 56 to the metronomic chemotherapy group (median age, 13 years; 42 male [75.0%]). At a median follow-up of 2.9 months, 100% of the patients had disease progression by 6 months in the placebo group vs 96.4% in the metronomic chemotherapy group (P = .24). Median PFS and OS in the 2 groups was similar (hazard ratio [HR], 0.69; 95% CI, 0.47-1.03 [P = .07] for PFS; and HR, 0.74; 95% CI, 0.50-1.09 [P = .13] for OS). In post hoc subgroup analysis, cohorts receiving more than 3 cycles (HR for PFS, 0.46; 95% CI, 0.23-0.93; P = .03) and those without a bone sarcoma (ie, neither primitive neuroectodermal tumor nor osteosarcoma) (HR for PFS, 0.39; 95% CI, 0.18-0.81; P = .01) appeared to benefit from metronomic chemotherapy. CONCLUSIONS AND RELEVANCE: Metronomic chemotherapy does not improve 6-month PFS, compared with placebo, among pediatric patients with extracranial progressive solid malignant tumors . However, patients without bone sarcoma and those able to tolerate therapy for more than 3 cycles (9 weeks) benefit. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01858571.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Pramanik R, Agarwala S, Gupta YK, et al. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 28384657. doi:10.1001/jamaoncol.2017.0324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。